CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.
Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.
One of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs for blood cancers. While these therapies have shown great promise for some indications, we still lack effective therapies for many others. A novel route to address this is to the restore innate immunitys ability to fight cancer.
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.
MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus.
At the CPHI, the world’s largest pharmaceutical event, which attracted 40,405 visitors this year, it became evident that the COVID-19 pandemic has had an extremely positive impact on the (bio)pharmaceutical sector. A new CPHI annual survey shows how business will develop in the future. Particularly, the prospects for CDMOs and CROs are excellent.
At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF).
A child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy.
Unit-dose?The SARS-CoV2 pandemic caused 6.3 million deaths and contaminated 545 million people across the world. In spite of the rapid development and approval of vaccines, the shortages of consumables like glass vials limited the distribution of prophylactic vaccines. Blow-Fill-Seal (BFS) is an alternative solution with advantages that could play an important role in vaccine distribution worldwide.